DRUG logo

Bright Minds Biosciences (DRUG)

Profile

Full Name

Bright Minds Biosciences Inc.

Ticker Symbol

DRUG

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

March 22, 2021

Indexes

Not included

Website

http://brightmindsbio.com

Employees

-

Key Details

Price

$31.84(-1.76%)

Market cap

$224.28M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$0.48(+67.44% YoY)

PE ratio

-

Next earnings date

May 15, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$31.84
DRUG price is $31.84

30-Day Relative Volume

0.68
DRUG 30-day relative volume is 0.68

Price Performance

Price Today change

-1.76%
DRUG price is down -1.76% today

Price YTD change

-11.6%
DRUG price is down -11.6% since January 1st

Price 1-year change

+2692.98%
DRUG price is up +2692.98% year-on-year

Price 3-year change

+394.41%
DRUG price is up +394.41% over the past 3 years

Price Range

Price All-time high

$79.02
DRUG price is currently -59.71% below its historical high of $79.02

Price 3-year low

$0.93
DRUG price is currently +3323.66% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$224.28M
DRUG market capitalization is $224.28 million

Market cap 3-year change

+1369.83%
DRUG market capitalization is up +1369.83% over the past 3 years

Market cap All-time high

$383.60M
DRUG market capitalization is currently -41.53% below its historical high of $383.60 million

Market cap sector rank

59.46%
DRUG market capitalization is higher than 59.46% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+57.8%
DRUG shares outstanding is up +57.8% year-on-year

Shares Outstanding 3-Year Change

+197.29%
DRUG shares outstanding is up +197.29% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

-1.94
DRUG beta is -1.94

200-day SMA

$24.34
DRUG price is currently +30.79% above its 200-day simple moving average

50-day SMA

$35.87
DRUG price is currently -11.24% below its 50-day simple moving average

RSI

47.18
DRUG 14-day relative strength index is 47.18

Volume

0.68
DRUG 30-day relative volume is 0.68

ATR

$2.79
DRUG average true range is $2.79

10-day Historical Volatility

103.07%
DRUG 10-day historical volatility is 103.07%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
DRUG annual revenue value is unknown

Revenue Analysts estimate

-
DRUG annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
DRUG annual revenue 1-year change is unknown

Revenue Sector rank

-
DRUG annual revenue is unknown

EPS

EPS

-$0.48
DRUG annual earnings per share is -$0.48

EPS Analysts estimate

-$1.96
DRUG annual earnings per share is currently -75.60% lower than the consensus analysts' forecast

EPS 1-year change

+67.44%
DRUG annual earnings per share is up +67.44% year-on-year

EPS Sector rank

69.59%
DRUG annual earnings per share is higher than 69.59% of companies in Healthcare sector

Profit

Gross profit

-
DRUG annual gross profit value is unknown

Gross margin

-
DRUG annual gross profit margin value is unknown

Operating profit

-$2.07M
DRUG annual operating income is -$2.07 million

Operating margin

-
DRUG annual operating profit margin value is unknown

Net income

-$2.06M
DRUG annual net profit is -$2.06 million

Net margin

-
DRUG annual net profit margin value is unknown

Expenses

Total expenses

$2.07M
DRUG annual total expenses is $2.07 million

Operating expenses

$2.07M
DRUG annual total operating expenses is $2.07 million

Cost of goods sold

-
DRUG annual cost of goods sold value is unknown

Selling, general & administrative expenses

$1.06M
DRUG annual SGA is $1.06 million

Depreciation and amortization

$53.90K
DRUG annual depreciation & amortization is $53.90 thousand

Interest expense

-
DRUG annual interest expense value is unknown

Income tax

-
DRUG annual income tax value is unknown

EBIT & EBITDA

EBIT

-$2.07M
DRUG annual earnings before interest & taxes is -$2.07 million

EBITDA

-$2.02M
DRUG annual EBITDA is -$2.02 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$4.52M
DRUG annual total assets is $4.52 million

Non current assets

$87.10K
DRUG annual long term assets is $87.10 thousand

Current assets

$4.43M
DRUG annual total current assets is $4.43 million

Cash and cash equivalents

$4.23M
DRUG annual cash & cash equivalents is $4.23 million

Accounts receivable

-
DRUG annual accounts receivable value is unknown

Inventory

-
DRUG annual inventory value is unknown

Liabilities

Total liabilities

$420.60K
DRUG annual total liabilities is $420.60 thousand

Long term liabilities

$29.30K
DRUG annual total long term liabilities is $29.30 thousand

Current liabilities

$391.30K
DRUG annual total current liabilities is $391.30 thousand

Accounts payable

$301.60K
DRUG annual accounts payable is $301.60 thousand

Debt

Total debt

$88.10K
DRUG annual total debt is $88.10 thousand

Total debt 1-year change

+62.85%
DRUG annual total debt is up +62.85% year-on-year

Long term debt

$29.30K
DRUG annual long term debt is $29.30 thousand

Short term debt

$58.80K
DRUG annual short term debt is $58.80 thousand

Equity & Capital

Shareholders equity

$4.10M
DRUG annual stockholders equity is $4.10 million

Book value

$4.10M
DRUG annual book value is $4.10 million

Retained earnings

-$25.42M
DRUG annual retained earnings is -$25.42 million

Working capital

$4.04M
DRUG annual working capital is $4.04 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$1.36M
DRUG annual cash flow from operations is -$1.36 million

Cash from operations 1-year change

+73.88%
DRUG annual cash flow from operations is up +73.88% year-on-year

Cash from investing

-
DRUG annual cash flow from investing activities value is unknown

Cash from investing 1-year change

-
DRUG annual cash flow from investing activities 1-year change is unknown

Cash from financing

$595.70K
DRUG annual cash flow from financing activities is $595.70 thousand

Cash from financing 1-year change

-63.29%
DRUG annual cash flow from financing activities is down -63.29% year-on-year

CAPEX

CAPEX

-
DRUG annual capital expenditures value is unknown

CAPEX 1-year change

-
DRUG annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$1.36M
DRUG annual free cash flow is -$1.36 million

Free cash flow 1-year change

+73.88%
DRUG annual free cash flow is up +73.88% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
DRUG annual gross profit margin value is unknown

Operating margin

-
DRUG annual operating profit margin value is unknown

Net margin

-
DRUG annual net profit margin value is unknown

ROA & ROE

ROA

-45.57%
DRUG annual return on assets is -45.57%

ROE

-50.25%
DRUG annual return on equity is -50.25%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
DRUG price to earnings ratio value is unknown

PE ratio Sector rank

-
DRUG price to earnings ratio is unknown

PB Ratio

PB ratio

5.57
DRUG price to book ratio is 5.57

PB ratio Sector rank

85.1%
DRUG price to book ratio is higher than 85.1% of companies in Healthcare sector

PS Ratio

PS ratio

-
DRUG price to sales ratio value is unknown

PS ratio Sector rank

-
DRUG price to sales ratio is unknown

Enterprise value

Enterprise value

$184.07M
DRUG enterprise value is $184.07 million

Enterprise value Sector rank

58.4%
DRUG enterprise value is higher than 58.4% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-95.69
DRUG EV/EBITDA is -95.69

EV/EBITDA Sector rank

1.31%
DRUG EV/EBITDA is higher than 1.31% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

11.32
DRUG annual current ratio is 11.32

Quick ratio

-
DRUG annual quick ratio value is unknown

Leverage

Debt to equity

0.02
DRUG annual debt to equity ratio is 0.02

Interest coverage ratio

-
DRUG annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
DRUG piotroski f-score value is unknown

Altman Z-Score

-
DRUG altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Feb 19, 25 HC Wainwright & Co.
Buy
Jan 23, 25 Piper Sandler
Overweight
Jan 10, 25 HC Wainwright & Co.
Buy
Jan 10, 25 Cantor Fitzgerald
Overweight
Nov 25, 24 Baird
Outperform

Institutional Ownership

Similar stocks

Atlantic International (ATLN)
DCGO logo
DocGo (DCGO)
ITOS logo
iTeos Therapeutics (ITOS)
LFMD logo
LifeMD (LFMD)
OABI logo
OmniAb (OABI)
THRD logo
Third Harmonic Bio (THRD)
QSI logo
Quantum-Si incorporated (QSI)
ATXS logo
Astria Therapeutics (ATXS)
LFCR logo
Lifecore Biomedical (LFCR)
  • What is the ticker symbol for Bright Minds Biosciences?
  • Does Bright Minds Biosciences pay dividends?
  • What sector is Bright Minds Biosciences in?
  • What industry is Bright Minds Biosciences in?
  • What country is Bright Minds Biosciences based in?
  • When did Bright Minds Biosciences go public?
  • Is Bright Minds Biosciences in the S&P 500?
  • Is Bright Minds Biosciences in the NASDAQ 100?
  • Is Bright Minds Biosciences in the Dow Jones?
  • When was Bright Minds Biosciences's last earnings report?
  • When does Bright Minds Biosciences report earnings?

What is the ticker symbol for Bright Minds Biosciences?

The ticker symbol for Bright Minds Biosciences is NASDAQ:DRUG

Does Bright Minds Biosciences pay dividends?

No, Bright Minds Biosciences does not pay dividends

What sector is Bright Minds Biosciences in?

Bright Minds Biosciences is in the Healthcare sector

What industry is Bright Minds Biosciences in?

Bright Minds Biosciences is in the Biotechnology industry

What country is Bright Minds Biosciences based in?

Bright Minds Biosciences is headquartered in United States

When did Bright Minds Biosciences go public?

Bright Minds Biosciences's initial public offering (IPO) was on March 22, 2021

Is Bright Minds Biosciences in the S&P 500?

No, Bright Minds Biosciences is not included in the S&P 500 index

Is Bright Minds Biosciences in the NASDAQ 100?

No, Bright Minds Biosciences is not included in the NASDAQ 100 index

Is Bright Minds Biosciences in the Dow Jones?

No, Bright Minds Biosciences is not included in the Dow Jones index

When was Bright Minds Biosciences's last earnings report?

Bright Minds Biosciences's most recent earnings report was on Feb 13, 2025

When does Bright Minds Biosciences report earnings?

The next expected earnings date for Bright Minds Biosciences is May 15, 2025
On this page